- Home
- CRNX vs IONS Comparison
CRNX vs IONS Comparison
Compare CRNX & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- IONS
- Stock Information
- Founded
- CRNX 2008
- IONS 1989
- Country
- CRNX United States
- IONS United States
- Employees
- CRNX N/A
- IONS N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- CRNX Health Care
- IONS Health Care
- Exchange
- CRNX Nasdaq
- IONS Nasdaq
- Market Cap
- CRNX 5.2B
- IONS 6.0B
- IPO Year
- CRNX 2018
- IONS 1991
- Fundamental
- Price
- CRNX $54.66
- IONS $37.33
- Analyst Decision
- CRNX Strong Buy
- IONS Buy
- Analyst Count
- CRNX 10
- IONS 18
- Target Price
- CRNX $74.40
- IONS $62.00
- AVG Volume (30 Days)
- CRNX 594.1K
- IONS 1.5M
- Earning Date
- CRNX 11-12-2024
- IONS 11-06-2024
- Dividend Yield
- CRNX N/A
- IONS N/A
- EPS Growth
- CRNX N/A
- IONS N/A
- EPS
- CRNX N/A
- IONS N/A
- Revenue
- CRNX $1,038,999.00
- IONS $803,067,000.00
- Revenue This Year
- CRNX N/A
- IONS N/A
- Revenue Next Year
- CRNX $195.21
- IONS $19.61
- P/E Ratio
- CRNX N/A
- IONS N/A
- Revenue Growth
- CRNX N/A
- IONS 30.57
- 52 Week Low
- CRNX $33.67
- IONS $33.33
- 52 Week High
- CRNX $62.53
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- CRNX 45.55
- IONS 52.98
- Support Level
- CRNX $52.85
- IONS $36.39
- Resistance Level
- CRNX $56.15
- IONS $38.90
- Average True Range (ATR)
- CRNX 2.36
- IONS 1.33
- MACD
- CRNX -0.32
- IONS 0.23
- Stochastic Oscillator
- CRNX 29.91
- IONS 51.63
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.